No need for alarm

14 September 2015
Volume 31 · Issue 6

A chance finding arising out of post mortems on the brain tissue of eight people who died from Creutzfeldt-Jakob disease (vCJD) should not on its own influence current provision of endodontics in the UK, says Julian Webber of the Harley Street Centre for Endodontics.

The autopsies of six out of the eight patients found they had amyloid deposits in the brain. Amyloid is an abnormal protein and a shared biomarker of both Alzheimers and vCJD.

All eight people had died between the ages of 31 and 51 from vCJD contracted as a result of growth hormone injections from contaminated sources, withdrawn in 1985. Today, growth hormone injections are derived from synthetic sources.

The research team from UCL led by John Collinge, whose findings have just been published in Nature, say there is a theoretical risk that the amyloid protein could be spread accidentally during surgical procedures, in the same way as CJD.

Julian Webber comments: “This is a chance finding and the amyloid protein may have been present as a result of the injections of contaminated growth hormone. There is no plausible scientific basis for believing that transmission can occur from one patient to another.

“In the UK we already operate to a gold standard in endodontics, following the advice of the Chief Dental Officer in 2007, that all files and reamers should be considered as single use. This is despite there being no evidence to support the presence of CJD prions in human dental pulp. There should be no attempt to alter guidelines without further research and clear evidence.”

Register now to continue reading

Thank you for visiting The Dentist. To read more, please register. Registration to the-dentist.co.uk allows you to enjoy the following benefits:

WHAT’S INCLUDED

  • Unlimited access to the latest news, articles and video content

  • Monthly email newsletter

  • Podcasts and members benefits, coming soon!